Agomelatine, an antidepressant melatonergico
Agomelatine (Valdoxan) is the first antidepressant melatonergic. The therapeutic efficacy of the drug was demonstrated in the treatment of major depressive disorder at a dose of 25mg/die. For its pharmacological profile, agomelatine does not induce side effects typical of other therapies, such as selective serotonin reuptake inhibitors (eg, gastrointestinal disorders, weight gain, serotonin syndrome and insomnia). A placebo-controlled study in patients with depressive disorder major, who compared the effects of agomelatine with those of venlafaxine (Efexor) on sexual dysfunction, have demonstrated a very favorable Agomelatine. In addition, the Agomelatine has proven to be as effective as venlafaxine. A placebo-controlled study evaluated the effect of abrupt cessation of treatment, highlighting the absence of withdrawal symptoms with agomelatine in contrast to that observed with paroxetine (Eutimil / Daparox / Sereupin / Seroxat). Agomelatine has also been shown to positively influence the abnormal circadian rhythms in depressed patients, significantly improving all phases of disturbed sleep and sleep quality, with a favorable impact Supervision throughout the day. The clinical trial data so far indicate that the Agomelatine represents a new approach to the treatment of depression, combining the effectiveness of a favorable safety profile and sleep regulation.
Rouillon F et al, Int Clin Psychopharmacol 2006; 21 Suppl 1: S31-S35
0 comments:
Post a Comment